Hepion Pharmaceuticals, INC 8-K filings

Hepion Pharmaceuticals' interim CEO and CFO, John Cavan, has departed for personal reasons, with executive chairman John Brancaccio stepping in as interim CEO and CFO effective August 6, 2024.

Hepion Pharmaceuticals will merge with Pharma Two B, a late-clinical stage company developing a Parkinson's disease treatment, and secure $11.5 million in private financing.

Hepion Pharmaceuticals has appointed Michael Purcell as a new director and chair of the Audit Committee, effective March 5, 2024.

Hepion Pharmaceuticals reports the resignation of Dr. Gary Jacob from the Board of Directors and the appointment of John Brancaccio as the new Chairman, effective February 20, 2024.

Hepion Pharmaceuticals has entered into a warrant inducement agreement, resulting in approximately $2.06 million in gross proceeds through the exercise of existing warrants at a reduced price.

Anand Reddi resigned from Hepion Pharmaceuticals' Board of Directors, effective February 7, 2024.